新股申购 | 华昊中天医药-B一手入场费4444.38港元，引入百洋医药等多家基石

港股新股“华昊中天医药”招股启动

公司概况

华昊中天医药是一家专注于合成生物学技术驱动的生物医药公司，致力于开发肿瘤创新药。凭借强大的研发实力和创新能力，公司旨在为全球患者提供高效、安全的治疗方案。为了加速产品研发和市场拓展，华昊中天医药决定在港股市场首次公开募股（IPO）。

招股信息概览

华昊中天医药于2024年10月23日至10月28日全球招股，计划发行1458.8万股H股。其中，香港发售约占10%，国际发售约占90%。发行价格区间为每股16港元至22港元，每手交易单位为200股，预计2024年10月31日在联交所开始买卖。

募集资金将主要用于以下几个方面：

• 核心产品临床试验：约44.9%的资金将用于资助核心产品的进行中及计划进行的临床试验。
• 其他产品研发：约38.9%的资金将用于资助核心产品以外的临床试验、产品临床前研究及研究者发起试验。
• 商业化能力加强：约3.0%的资金将用于加强国内商业化能力及建立全球营销网络。

市场前景与投资亮点

市场前景广阔

随着全球人口老龄化和癌症发病率的上升，肿瘤创新药市场需求持续增长。华昊中天医药在肿瘤创新药领域具有显著市场优势，其合成生物学技术也为未来发展提供了强大支撑。

投资亮点

• 创新能力：公司拥有强大的研发团队和创新能力，持续推出具有竞争力的新药产品。
• 市场前景：随着产品推出和市场拓展，公司业绩有望持续增长。
• 管理团队：经验丰富、能力出众的管理团队确保公司稳健运营和持续发展。

风险提示与投资策略

尽管华昊中天医药招股前景看好，但投资者需注意潜在风险。生物医药行业研发周期长、投入大，且面临诸多不确定性。因此，建议投资者：

• 充分了解公司财务状况、研发实力、市场前景及挑战。
• 关注公司后续公告和业绩表现，及时调整投资策略。
• 谨慎决策，考虑长期持有策略以应对市场波动。

综上所述，华昊中天医药的招股为公司发展带来重要机遇，也为投资者提供难得的投资机会。然而，市场存在不可预测风险，投资者应充分了解相关信息并谨慎决策。通过关注公司核心竞争力、市场前景及潜在风险，投资者可以更好地把握这一投资机会。

Company profile

Biostar Pharmaceutical is a biopharmaceutical company focused on synthetic biology technology and committed to the development of innovative oncology drugs. With strong research and development capabilities and innovation capabilities, the company aims to provide efficient and safe treatment solutions for patients worldwide. In order to accelerate product development and market expansion, Biostar Pharmaceutical decided to launch an initial public offering (IPO) in the Hong Kong stock market.

Offering information overview

From October 23 to October 28, 2024, Biostar Pharmaceutical plans to issue 14.588 million H shares. Of these, Hong Kong sales accounted for about 10% and international sales accounted for about 90%. The offering price range is HK $16 to HK $22 per share, with each lot of 200 shares expected to start trading on the Stock Exchange on 31 October 2024.

The funds raised will be mainly used in the following aspects:

· Core product clinical Trials: Approximately 44.9% of the funds will be used to fund ongoing and planned clinical trials of core products.

· Other product development: Approximately 38.9% of the funding will be used to fund clinical trials, product preclinical studies, and investigator-initiated trials outside the core product.

· Enhanced commercialization capabilities: Approximately 3.0% of the capital will be used to strengthen domestic commercialization capabilities and establish a global marketing network.

Market prospects and investment highlights

Broad market prospect

As the global population ages and the incidence of cancer rises, the market demand for innovative oncology drugs continues to grow. Biostar Pharmaceutical has a significant market advantage in the field of oncology innovative drugs, and its synthetic biology technology also provides a strong support for future development.

Investment highlights

· Innovation ability: The company has a strong R & D team and innovation ability, and continues to launch competitive new drug products.

· Market prospects: With product launch and market expansion, the company's performance is expected to continue to grow.

· Management team: Experienced and competent management team ensures the company's steady operation and sustainable development.

Risk tips and investment strategies

Although Biostar Pharmaceutical IPO prospects, but investors need to pay attention to potential risks. Biomedical industry research and development cycle is long, investment is large, and faced with many uncertainties. Therefore, investors are advised to:

· Fully understand the company's financial position, R&D strength, market prospects and challenges.

· Pay attention to the company's subsequent announcements and performance, and adjust investment strategies in a timely manner.

· Make prudent decisions and consider long-term holding strategies to cope with market volatility.

To sum up, the IPO of Biostar Medicine brings important opportunities for the development of the company, and also provides investors with rare investment opportunities. However, there are unpredictable risks in the market, and investors should fully understand the relevant information and make prudent decisions. By focusing on the company's core competitiveness, market prospects and potential risks, investors can better grasp this investment opportunity.